University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 11S-12-1

A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Cross-Over, Phase II.5 Study of Saracatinib (AZD0530), a Selective Src Kinase Inhibitor, in Patients with Recurrent Osteosarcoma Localized to the Lung.

Type: Treatment
Phase: Phase II
Status: Not Open (Closed)
Treatments: Chemotherapy: Systemic
Randomized: Yes
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  James Hu, M.D.
Other Trial Staff:  Charlean Ketchens, R.N., Lagrimas Ilagan, D.M., Ernesto Duverger, D.M., Yvette Viverette, R.N., Torsten Fischer, R.N.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.